# Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol

> **NCT01451918** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 8 (actual)

## Conditions studied

- Dyslipidaemia
- Insulin Resistance

## Interventions

- **DRUG:** Resveratrol

## Key facts

- **NCT ID:** NCT01451918
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2014-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01451918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01451918, "Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01451918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*